Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial

Authors :

Sr. No.	Name	Affiliation	Email ID
1.	Prof. Dr. Suresh B. Patankar*	AMAI Charitable Trust, Pune	sureshpatankarace@gmail.com
2.	Dr. Hrishikesh Rangnekar	Quest Clinical Services, Pune	h.rangnekar@questclinicalservices.c o.in dr.rangnekar@gmail.com
3.	Dr. Kalpana Joshi	Dept. of Biotechnology, Sinhgad College of Engineering, Pune	kalpanajoshi1788@gmail.com
4.	Dr. Kishor Suryawanshi	YCM Hospital, Pune	drkishorsuryawanshi@gmail.com
5.	Dr. Pravin Soni	YCM Hospital, Pune	drpravinsoni18@gmail.com
6.	Dr. Anupama Gorde	Sinhgad Institute of Dental Sciences, Pune	drpatankar02@yahoo.in
7.	Dr. Tejas Shah	Krsnaa Diagnostics Pvt. Ltd. Pune	sktejas09@gmail.com
8.	Mr. Sagar Patankar	AMAI Charitable Trust, Pune	sagarpatankar87@gmail.com
9.	Dr. Diwakar Jha	SHRIPAD Medisearch Pvt. Ltd., Pune	drdjha@gmail.com
10.	Dr. Rajesh Raje	AMAI Charitable Trust, Pune	researchace2@gmail.com

Corresponding Author*

1 Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to

2

moderate COVID-19: A randomized, double-blind, placebo-controlled trial

3 ABSTRACT

4 Objective: To assess the efficacy and safety of polyherbal formulation (designated as IP) in
5 comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate
6 novel corona virus disease 2019 (COVID-19)

Methods: Laboratory proved patients of mild to moderate COVID-19 disease were randomized to either placebo or IP as an add-on to SoC. Using quantitative reverse transcription-polymerase chain reaction (qRTPCR), we assessed the effect on viral load (VL). Change in immunological parameters such as blood lymphocyte subset, serum immunoglobulin was determined. The clinical improvement was assessed using a numerical rating scale (NRS) and WHO ordinal scale. Patients were followed for 30 days after randomization.

13 **Results:** In total, 72 patients were randomized to either placebo (n=33) and IP (n=39). Fifty-two 14 patients (n=21 in placebo and n=31 in IP arm) had qRT-PCR on day 0 and day 4. There was 15 significant reduction in VL in IP arm (from 662081 copies/mL on day 0 to 48963 copies/mL on day 4; 16 p=0.002) but not in the placebo arm (from 385670 copies/mL on day 0 to 66845 copies/mL on day 4, 17 p=0.106). Change in the NRS score and WHO ordinal scale score was significant in both treatment 18 arms. However, the difference between the two groups was statistically significant in favour of drug 19 group, . The increase in Th1 response was significant in the IP arm (p=0.023) but not in the placebo 20 arm (p=0.098), thus implying immunomodulatory activity in the drug. No safety concerns were 21 observed in any of the trial participants.

22 **Conclusion**: This study finds that polyherbal formulation reduces viral load and contributes to 23 immunomodulation and improvement in clinical conditions when used as add-on to the standard care

in patients with mild to moderate COVID-19 without any side effects. These findings need to befurther confirmed in a large, prospective, randomized study.

- 26 Keywords: COVID-19, herbal medication, viral load, immuno modulation.
- 27

28 INTRODUCTION

29 Novel coronavirus disease 2019 (COVID-19) pandemic is a significant contributor to morbidity and 30 mortality in affected individuals. World Health Organization, as of 23April 2021, reports 144,358,956 31 confirmed cases of COVID-19, including 3,066,113 deaths [1]. Since its first identification in December 2019, there is now a fair understanding of the COVID-19 disease pathogenesis. Hyper 32 33 stimulated immune response causing systemic inflammatory response syndrome or "cytokine storm" 34 is known to be implicated in progression to severe COVID-19 [2,3]. Such immune response correlates 35 linearly with the viral load that in turn correlates with disease severity [4,5]. Modulating the immune 36 response in COVID-19 is now an established treatment approach. The RECOVERY trial showed that 37 dexamethasone 6 mg once daily for ten days significantly lowered 28-day mortality in hospitalized 38 COVID-19 patients [6]. Also, treatment with specific interleukin -6 inhibitor tocilizumab did not 39 improve survival but reduced the likelihood of progression to the composite outcome of mechanical 40 ventilation or death [7]. With Itolizumab, an anti-CD6 humanized monoclonal antibody with an 41 immunomodulating action on Teffector cells, there was a significant reduction in 30-day mortality 42 along with significant improvement in clinical immunological, and oxygen parameters [8]. Thus, 43 modulating immune response can help to improve clinical parameters and mortality outcomes, 44 especially in hospitalized moderate to severe COVID-19 patients.

Herbal formulations have long been assessed for their potential immune modulating effects [9,10]. In
an in-vitro study (*data on file*), we observed that a combination of herbals (IP) such as Ashwagandha

47 (Withaniasomnifera), Vidanga (Embeliaribes), Guduchi (Tinospora cordifolia), Haritaki (Terminalia 48 chebula), Aamalaki (Emblica officinalis), Shatavari (Asparagus racemosus), Yashtimadhu 49 (Glycyrrhiza glabra), Ginger (Zinziber officinale), Pippali (Piper longum), Shankha Bhasma and 50 Jasath Bhasma showed antiviral activity against SARS-CoV-2. As the search for potential antiviral 51 and immune modulating therapy for COVID-19 is ongoing, this could be potentially beneficial. 52 Therefore, we conducted this randomized, double-blind, placebo-controlled study to determine the 53 effect of the polyherbal formulation on viral load and immunological parameters and clinical 54 improvement in mild to moderate COVID-19 disease when used as an add-on to the SoC.

55 MATERIALS AND METHODS

56 Design and Population

57 This study was a double-blind, randomized, placebo-controlled trial to assess the safety and efficacy 58 of polyherbal drug formulation (designated as IP) in patients with mild to moderate COVID-19. The 59 study was conducted at a single center in Pune, Maharashtra, India. We enrolled adults of age 18 60 years and above, diagnosed with laboratory-proven COVID-19 disease of mild to moderate severity 61 who were admitted to the hospital as per the isolation protocol. Pregnant and lactating females, any 62 respiratory symptoms of >7 days, patients with known pathology affecting the respiratory system, 63 diagnosed hematological disorders, patients with a terminal illness, any other condition which in the 64 view of the investigator would interfere with the general clinical well-being of the participant and 65 those not willing to participate in the study were excluded. The trial was conducted as per the ethical 66 principles of the Declaration of Helsinki, good clinical practice recommendations and applicable local 67 regulatory guidelines. The study was approved by the Board of Research Studies (BORS) and 68 Institutional Ethics Committee of Yashwantrao Chavan Memorial Hospital, Pimpri, Pune. Informed 69 consent was obtained from all the participants before enrolment. The study was registered with the

70 clinical trial registry of India (CTRI/2020/07/026570). The study protocol was published in a peer-

71 reviewed journal [11].

72 Study treatments and follow-ups

73 Patients with a known positive status of RT-PCR for SARS-CoV-2 disease were screened for the 74 study. Eligible and consenting patients were enrolled. Patients were randomized using computer-75 generated randomization codes to receive either IP or placebo as an add-on to the recommended 76 standard care (SoC) for COVID-19. IP in the title was a combination of IP1 and IP2, having the 77 following ingredients. IP1: Shunthi (Zinziber officinale), Vidanga (Embelia ribes), Yashtimadhu 78 (Glycyrrhiza glabra), Shankhabhasma and Jasath Bhasma. IP2 contains: Haritaki (Terminalia 79 chebula), Guduchi (Tinospora cordifolia), Shatavari (Asparagus racemosus), Aamalaki (Emblica 80 officinalis), Pippali (Piper longum), Ashwagandha (Withania somnifera) and Jasath Bhasma. The 81 investigational products were manufactured per API guidelines. Patients were advised to take one 82 capsule, two times a day (of each IP1 and IP2) or placebo, after meals. Patients received a prepacked 83 carton of study treatment for a total duration of 30 days. Capsule IP1 and IP2 were given for the first 84 15 days, and last 15 days they were given only IP2. Patients receiving placebo also received 2 85 capsules twice a day for first 15 days and for next 15 days, one capsule twice a day (Image 1). All the 86 patients continued their routine diet and physical activity and other prescribed treatment as per Indian 87 Council of Medical Research (ICMR) and World Health Organization (WHO) guidelines in 88 circulation at the time of study conduct.

During baseline visit (Day 0) nasopharyngeal swab was taken for qRTPCR, numerical rating scale (NRS) was filled for clinical status and the blood was withdrawn for various immunological inflammatory and safety markers. Patients had three follow-ups during the 30-day treatment period. First follow-up visit was done at day 4±1. qRTPCR, NRS was repeated at this visit and any clinical adverse events were recorded. Second follow-up was done clinically or telephonically (if they were

94 discharged) on day 15±2 to record any clinical deterioration in clinical condition and to record 95 adverse effects if any. Last follow-up was at day 30±2 to document clinical condition, adverse effects 96 and perform laboratory investigations. In this last follow-up, study personnel visited patients in their 97 homes to avoid their repeat visit to site as it was active COVID-19 hospital. Patients were asked to 98 visit any time if they observed any deterioration in clinical condition or had developed any untoward 99 reactions.

100 *Quantitative estimation of viral load using qRTPCR*

101 Three viral loci RdRP, N gene and E gene and a human gene as internal control (RNaseP) were 102 detected using GenePath Diagnostics' indigenously developed qRTPCR assay, CoViDx One v2.1.1 103 keeping appropriate controls and standards. Ten micro litres of extracted nucleic acid was used as an 104 input for the qRT-PCR. Quantitative estimation for each genomic target was performed using 105 standards, for which the number of genome copies were already known. The threshold cycle (Ct 106 value) for each genomic target was extrapolated to the viral load of standards to estimate the number 107 of copies/uL which were then converted to copies/mL for each gene for each sample. Average number 108 of copies/ ml was calculated for each sample that accounts for the approximate viral load in the 109 sample. Ct values for control human gene (RNaseP) ensured the adequacy of sample and served as 110 control for nucleic acid extraction and nucleic acid amplification.

On the day of first encounter with patients, they were subjected to thorough clinical and laboratory investigations. After signing of informed consent, their demographic details, and clinical parameters were recorded. Oxygen saturation was assessed using pulse oximeter. We investigated viral load (VL) with quantitative RTPCR for COVID-19, and blood was drawn for lymphocyte subset analysis (absolute neutrophil count, absolute lymphocyte count, TH1, TH2, Treg cells, NK Cells and CD markers such as CD3, CD4, CD3: CD8 ratio) as well as serum IgG and IgM levels (not specific to COVID-19). Liver function tests and renal function tests were performed as a part of safety

assessment. Blood investigations were repeated on day 30 for immunological markers, and for safety

assessments. We performed all the tests at a single accredited laboratory .

120 *Outcome measures*

- 121 Primary efficacy outcome measure was change in viral load. Secondary efficacy outcome measures
- 122 were change in disease severity score and change in immunological and inflammatory markers.
- 123 Numerical Rating Scale (NRS) was used for overall disease severity. 0 was considered for normal, 1

to 3 for mild, 4 to 6 for moderate and 7 to 10 for severe severity of the disease. Patients were asked to

- 125 rate the disease severity on the NRS. Also, change in immunological parameters such as lymphocyte
- 126 subset analysis (TH1, TH2, Th17),NK Cells and CD markers, serum IgG and IgM levels and Covid19
- 127 antibodies were assessed. Inflammatory and other markers like C reactive protein and D-Dimer, Sr.
- 128 Ferritin were assessed in a small portion of enrolled subjects. Primary safety measure was incidence
- 129 of adverse reactions (clinical and/or laboratory parameters).

Two sided significance level	95]	-	
(1 alpha)			Kelsey	Fleiss
Power (1-beta. % chance of	80	Sample Size Exposed	28	27
detecting)		Sample Size Non exposed	28	27
Ratio of sample size,	1	Total Sample Size	56	54
Unexposed/exposed		References:		
% of Unexposed with	5	Kalsay at al Mathada in Oha	amustional	
outcome		Kelsey et al, Methods in Obs		
% of Exposed with outcome	35	Epidemiology, 2 nd edition, ta		
Odds ratio	10	Statistical Methods For Rates	s and Prop	ortions,
Risk/ Prevalence ratio	7	formulas 3.18 and 3.19.		
Risk/ Prevalence	30	Results are rounded up to t	he neares	t integer

Statistical analysis: Sample size:

137 Results from OpenEpi, Version 3, open source calculator –SSC cohort.

138 Considering drop-outs, 72 patients were enrolled.Data was entered in to the Microsoft excel sheet

- 139 version 2016 and was analyzed with SPSS software. Categorical variables were presented as
- 140 frequency and percentage. Statistical comparisons of categorical data were done with Chi square test

or Fischer exact test. For continuous variables, normal distribution was assessed by plotting the histograms. Normally distributed data was presented using mean and standard deviations (SD) and non-normally distributed data presented as median (Interquartile range (IQR) 25-75). Student t-test and Mann-Whitney U test were applied accordingly to test the statistical differences in continuous independent variables. For before and after analysis, we used paired t test and Wilcoxon signed rank sum test to determine the statistical significance. P value <0.05 was considered significant for all comparisons.

148 **RESULTS**

149 Participant enrolment flow

150 Between August and September 2020, we screened 92 patients of which 72 were randomized to either

151 placebo (n=33) or IP (n=39). Figure 1 shows study flow of the participant. Overall, 66 patients

152 completed the 30-day follow-up (placebo n=31; IP n=35).

153 *Demographic parameters* (Table no. 1)

Mean age was 43 years and 47 years in placebo and IP group (p=0.336). There was no difference in proportion of males and females in two groups (p=0.150).

156 *Effect on Viral Load (VL)* (Table no. 2)

Overall, 52 patients had undergone qRT-PCR on day 4 (31 in drug arm, 21 in placebo arm). IP treatment was associated with significant reduction in median VL (from 662081 virus copies/mL (IQR: 56904 to 19485712) on day 0 to 48963 copies/mL (IQR: 8774 to 1248257) day 4; p=0.002)). In placebo group also, there was reduction in VL but it was non-significant (from 385670 copies/mL (IQR: 30807 to 131511846) on day 0 to 66845 copies/mL (IQR: 11978 to 836124.5) on day 4

162 (p=0.106)). Standard of care was continued in both the groups.

163 *Clinical Assessment* (Table No. 3)

164 In the IP arm, there was significant reduction in NRS from day 0 to day 4 (4.3 (\pm 1.13) 1.74+(1.03), 165 p<0.0001). In Placebo arm as well, there was significant reduction in NRS score $(4.26\pm1.09$ to 166 3.16+1.03, p<0.0001). Baseline scores of both the groups were similar, with P value 0.78; the 167 difference between drug and placebo arm of 'after' was statistically highly significant. Later, upon 168 WHO ordinal scale was available, and retrospectively the scores were assigned to the patients' 169 condition, on day 0 and 4, IP arm was at 1.63 (± 0.84) and 1.03 (± 0.45) respectively with p value 170 0.0001; whereas, for placebo, these values were 1.71 (+0.78) and 1.26 (+0.63) with p value 0.03. P 171 value for drug arm was highly significant (>0.01).

172 Blood Biomarkers for immunity and inflammation

173 Changes in the inflammatory and immunological parameters are shown in Table4, between day 0 and 174 day 30. There was significant increase in absolute B cell count, absolute T cell count, absolute CD3, 175 CD4 and T helper cells as well as in the ratio of absolute CD3 and CD8 cells in both IP and placebo 176 arm. Change in absolute NK cell count was significant in placebo arm (p=0.020) but not in drug arm 177 (p=0.067). However, the magnitude of change was higher with IP than the placebo. The increase in 178 Th1 response was significant with IP treatment (p=0.023) but not with the placebo treatment 179 (p=0.098). The IgG antibodies reduced significantly in both placebo and IP arm. However, the effect 180 on IgM was non-significant in both groups. Covid antibodies were done on day 30. P value was not 181 significant, however around 20% more antibodies were noted in drug arm than placebo arm. Due to 182 inadequate sample size for CRP, D Dimer analysis was not feasible, however, average 50% reduction 183 in CRP was seen in SoC + drug arm whereas increase in the SoC + Placebo arm was seen. Similar 184 trend was seen for D Dimer also. Less number of patients opted for blood withdrawal during follow-185 up visits, and majority of them denied the blood letting.

186 Safety

There were no serious adverse events in the drug arm. One SAE occurred in placebo (+SoC) arm, which was 'prolongation of hospitalization' due to Covid related pneumonia, which got resolved later. LFT, RFT were not deranged in any of the patient, confirming safety. No drug-drug interaction with the SoC was seen.

191 **DISCUSSION**

192 Since December 2019, COVID -19 pandemic has been around the globe affecting millions of 193 individuals with significant contribution in morbidity and mortality. Despite being present for over a 194 year, definite therapies are limited for COVID-19. Modulating immunological response with steroids 195 has been found beneficial in hospitalized patients. However, in a large majority of patients who have 196 mild to moderate disease, effective treatment is necessary to prevent disease progression as well as 197 shedding of the virus to lower the transmission rates. Thus, reducing the viral load may assist in 198 achieving this objective. Viral load independently correlates with the risk of intubation and in-hospital 199 mortality [12,13]. We observed that IP was associated with significant reduction in viral load at day 4. 200 Reducing the viral load can help in early symptom recovery. It was evident as NRC was significantly 201 reduced.

Anti-viral activity of IP therefore can be helpful in early recovery of mild to moderate COVID-19 patients. Among currently employed antiviral agents, early treatment with favipiravir was reported to be associated with lower in VL at day 6 In hospitalized patients with COVID-19 [14].

Another antiviral agent that is used widely is remdesivir. However, remdesivir did not appear to affect rates of viral RNA load decline and mortality when compared with placebo in severe hospitalized COVID-19 patients [15]. Thus, initiating an antiviral agent before the peak viral load might be necessary. It may be difficult in clinical situation to predict the time of peak VL. In this study, IP was initiated as soon as individuals were tested positive for COVID-19 which might have helped in early improvement in clinical NRS score.

211 In addition to lowering VL, modulating immune response is now an established strategy. In 212 inflammatory response, Th1 pathway is associated with increase in the release of proinflammatory 213 cytokines like IL-1, IL-2, IL-12, TNF- α , IFN- γ , etc. Dysregulated immune response is associated with 214 development of cytokine storm. Most recent data demonstrated that COVID-19 might affect 215 lymphocytes, especially T lymphocytes. The absolute number of T lymphocytes, CD4+ T cells, and 216 CD8+ T cells decreased in infected individuals [16]. Immunomodulatory activity of single plants as 217 well as polyherbal formulations from Ayurveda are well reported [17]. Modulation of immune 218 response was evident in our study. Though placebo with SoC also showed significant effect, the 219 change in Absolute CD3, CD4 and T helper cells was numerically higher with IP treatment. Tregs and 220 their functions are compromised in severe COVID-19 patients, engendering unrestrained immune cell 221 activation resulting in damaged lungs in severe COVID-19 patients [18]. There is less reduction of 222 Tregs in the IP group as compared to the placebo group indicates a good inflammatory control in the 223 IP group. In severe COVID-19 patients, NK cell number and function is reduced, resulting in 224 decreased clearance of infected and activated cells, and unchecked elevation of tissue-damaging 225 inflammation markers. Restoration of NK cell effector functions has the potential to correct the 226 delicate immune balance required to effectively overcome SARS-CoV-2 infection [19.20]. Though the 227 statistical significance was not reached, increase in the number of NK cells was higher in IP group 228 than that of placebo. It probably indicates a potential to preserve and enhance the NK cell function 229 that might assist in viral clearance.

The in-vitro study conducted with study drug with remdesivir used as a positive control for viral inhibition. Inhibition of virus replication is determined based on the fold change in the Ct value in TStreated cells compared to the control. After 24 hours, % inhibition of E-gene was 9.10% and of N gene, it was 21.93%. After 48 hours, N gene inhibition was same as 24 hours however E gene was

further inhibited to 28.43% (*data on file*). Thus, clinical effects of viral load reduction identified with
 qRT-PCR are supported by the in-vitro data.

236 Protocol of the study was published in BMC's 'Trials' (2020)21:943. It was for the first time

that any study protocol pertaining to an Ayurveda intervention was published in the BMC

238 journal. (https://doi.org/10.1186/s13063-020-04906-x)

239 At individual level, each ingredient has unique properties and for example, Guduchi (Tinospora 240 cordifolia), Haritaki (Terminalia chebula), Amalaki (Eblica officinalis) has shown efficacy as anti-241 viral drugs, as an anti-oxidant, as an immune modulator; for Amalaki, a paper entitled, 'Structure-242 based drug designing for potential antiviral activity of selected natural products from Ayurveda 243 against SARS-CoV-2 spike glycoprotein and its cellular receptor'. At least four natural compounds 244 from Tinospora cordifolia showed high binding efficacy against SARS-CoV-2 targets involved in 245 attachment and replication of the virus, hence validating the merit of using *Tinospora cordifolia* in the 246 clinical management of infection caused by SARS-CoV-2. There is a certain efficacy of natural 247 compounds from Tinospora cordifolia against SARS-CoV-2 protease, surface glycoprotein and RNA 248 polymerase [21-22].Extract of T. chebula increased spleen lymphocyte proliferation. Based on RT-249 PCR analysis, the expression of cytokines (IL-2, IL-10 and TNF- α), was more in *T. chebula* -treated 250 than in other control groups [23]. Antioxidant properties of *Piper longum*, Zinziber officinale are also 251 well-known [24,25]. Antiviral activity of Vidanga (Embelia ribes) against Influenza virus and 252 antioxidant activity are well established [26]. Anti-inflammatory, antiviral effects of Yashtimadhu 253 (Glycyrrhiza glabra) are also well-known [27,28]. Shatavari (Asparagus racemosus) has many 254 activities including antioxidant and Immunomodulatory activities [29,30]. Minerals in the drug, 255 Shankha (incinerated conch shell) Bhasma is helpful to tackle gastric symptoms related to the disease 256 and Jasath Bhasma (zinc oxide) has an antiviral activity [31]. Jasath Bhasma is the purified zinc from 257 Ayurvedic process to yield optimum effect of zinc supplementation. Due to antioxidant effects of

Zinc, it protects against ROS and RNS. Zinc helps modulate cytokine release and induces proliferation of T cells and helps to maintain skin and mucosal membrane integrity. Zinc has a central role in cellular growth and differentiation of immune cells. It is essential for intracellular binding of tyrosine kinase to T cell receptors, required for T lymphocyte development and activation. Zinc supports Th1 response [32].

When we discuss about the possible mechanism of action, the approach is such that the combination acts 'as a whole'. There are multiple phyto-ingredients and a lot of chemical entities that act on multiple targets in various systems of the body. By virtue of such entity-rich drug, a milieu is created in the body, which is prepared to take care of the infection at multiple levels, organs and systems. Since it has shown positive results in reducing viral load and immune modulation of TH1 response, the same herbo-mineral formulation can have role for prophylactic action towards the virus. Limitation of the study is smaller number of participants.

Currently the formulation is known as Capsule CoviLyzerTM and Capsule Abayakasthaa plus^R, and is
manufactured by Ishaanav Nutraceuticals Pvt. Ltd.

272 CONCLUSION

With COVID-19 pandemic being ongoing in 2021, search for potential antiviral therapies is ongoing. This polyherbal combination drug was identified to provide effective antiviral activity in mild to moderate COVID-19 patients. Potential immunomodulatory effects observed with drug can also assist in preventing inflammatory tissue damage and may help reduce the intensity of systemic inflammatory syndrome. The investigational drug was found to be safe with no serious adverse event and it can be safely given along with Standard of Care to enhance its therapeutic activity in patients with mild to moderate COVID-19 disease for reducing viral load, cytokine storm and clinical

280 1	recovery.	Another	study on	severely	affected	Covid	patients	would	be	worthwhile to	explor	e of	this
-------	-----------	---------	----------	----------	----------	-------	----------	-------	----	---------------	--------	------	------

formulation, along with the standard of care.

282	Fundin	ng:	
283	The tria	al was funded by AMAI Trust, Pune	
284	Conflict of interest:		
285	Dr. Sur	esh Patankar is member of AMAI trust.	
286	Disclos	sures:	
287	None		
288			
289	REFE	RENCES	
290	1.	WHO Coronavirus (COVID-19) Dashboard. Available from https://covid19.who.int/	
291	2.	McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including	
292		Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like	
293		Disease. Autoimmun Rev. 2020; 19:102537. Doi:10.1016/j.autrev.2020.102537	
294	3.	Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19: a clue	
295		from innate immunity. Immunol Res. 2020; 68:161-168. Doi: 10.1007/s12026-020-09137-5.	
296	4.	Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or	
297		foe?. Life Sci. 2020; 256:117900. Doi:10.1016/j.lfs.2020.117900	
298	5.	Leligdowicz A, Feldmann J, Jaye A, Cotten M, Dong T, McMichael A, et al. Direct	
299		relationship between virus load and systemic immune activation in HIV-2 infection. J Infect	
300		Dis. 2010; 201:114-22. Doi: 10.1086/648733.	
301	6.	Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. RECOVERY	
302		Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med.	
303		2021; 384:693-704. Doi: 10.1056/NEJMoa2021436.	

304	7.	Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients
305		hospitalized with Covid-19 pneumonia. New England Journal of Medicine. 2021; 384:20-30.
306		Doi: 10.1056/NEJMoa2030340.
307	8.	Kumar S, De Souza R, Nadkar M, Guleria R, Trikha A, Joshi SR, et al. A two-arm,
308		randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and
309		safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert
310		OpinBiolTher. 2021; 21:675-686. Doi: 10.1080/14712598.2021.1905794
311	9.	Gautam M, Saha S, Bani S, Kaul A, Mishra S, Patil D, et al. Immunomodulatory activity of
312		Asparagus racemosus on systemic Th1/Th2 immunity: implications for immunoadjuvant
313		potential. J Ethnopharmacol. 2009; 121:241-7. Doi: 10.1016/j.jep.2008.10.028
314	10.	Vetvicka V, Vetvickova J. Immune enhancing effects of WB365, a novel combination of
315		Ashwagandha (Withaniasomnifera) and Maitake (Grifolafrondosa) extracts. N Am J Med Sci.
316		2011; 3:320-4. Doi: 10.4297/najms.2011.3320
317	11.	Rangnekar H, Patankar S, Suryawanshi K, Soni P. Safety and efficacy of herbal extracts to
318		restore respiratory health and improve innate immunity in COVID-19 positive patients with
319		mild to moderate severity: A structured summary of a study protocol for a randomised
320		controlled trial. Trials. 2020;21:943. Doi: 10.1186/s13063-020-04906-x.
321	12.	Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2
322		viral load predicts mortality in patients with and without cancer who are hospitalized with
323		COVID-19. Cancer cell. 2020; 38:661-71. Doi: 10.1016/j.ccell.2020.09.007.
324	13.	Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et als. Impact of
325		SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients
326		with Coronavirus Disease 2019. Clin Infect Dis. 2020:ciaa851. Doi: 10.1093/cid/ciaa851
327	14.	Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective,
328		randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients

329		with COVID-19. Antimicrobial agents and chemotherapy. 2020; 64: e01897-20. Doi:
330		10.1128/AAC.01897-20.
331	15.	Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe
332		COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;
333		395:1569-1578. Doi: 10.1016/S0140-6736(20)31022-9.
334	16.	Zhao R, Sun Y, Zhang Y, Wang W, Wang S, Wang C, et al. Distinguishable Immunologic
335		Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with
336		Nondiabetic Individuals. Mediators Inflamm. 2020; 2020:6914878. Doi:
337		10.1155/2020/6914878.
338	17.	Kumar D, Arya V, Kaur R, Bhat ZA, Gupta VK, Kumar V. A review of immunomodulators
339		in the Indian traditional health care system. Journal of Microbiology, Immunology and
340		Infection. 2012; 45:165-84. Doi: 10.1016/j.jmii.2011.09.030
341	18.	Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier JF, Bayry J. Potential of regulatory T-
342		cell-based therapies in the management of severe COVID-19. EurRespir J. 2020; 56:2002182.
343		Doi: 10.1183/13993003.02182-2020
344	19.	Mahmoudi S, Rezaei M, Mansouri N, Marjani M, Mansouri D. Immunologic Features in
345		Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. J
346		ClinImmunol. 2020; 40:974-976. Doi: 10.1007/s10875-020-00824-4.
347	20.	van Eeden C, Khan L, Osman MS, Cohen Tervaert JW. Natural Killer Cell Dysfunction and
348		Its Role in COVID-19. Int J Mol Sci. 2020; 21:6351. Doi: 10.3390/ijms21176351
349	21.	Sagar V, Kumar AHS. Efficacy of natural compounds from Tinosporacordifolia against
350		SARS-CoV-2 protease, surface glycoprotein and RNA polymerase. Virology. 2020:1-0. Doi:
351		10.21203/rs.3.rs-27375/v1

352	22.	Adhikari B, Marasini BP, Rayamajhee B, Bhattarai BR, Lamichhane G, Khadayat K, et al.
353		Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19:
354		A review. Phytother Res. 2021; 35:1298-1312. Doi: 10.1002/ptr.6893
355	23.	Aher V, Wahi A. Immunomodulatory activity of alcohol extract of Terminalia
356		chebularetzcombretaceae. Tropical Journal of Pharmaceutical Research. 2011;10(5):567-75.
357		Doi: 10.4314/tjpr.v10i5.5.
358	24.	Nahak G, Sahu RK. Phytochemical evaluation and antioxidant activity of Piper cubeba and
359		Piper nigrum. Journal of Applied Pharmaceutical Science. 2011; 1:153-157.
360	25.	Bekkouch O, Harnafi M, Touiss I, Khatib S, Harnafi H, Alem C, et al. In Vitro Antioxidant
361		and In Vivo Lipid-Lowering Properties of Zingiberofficinale Crude Aqueous Extract and
362		Methanolic Fraction: A Follow-Up Study. Evid Based Complement Alternat Med.
363		2019:9734390. Doi: 10.1155/2019/9734390.
364	26.	Vaghela JS, Sisodia SS. In vitro antioxidant activity of Embeliaribes fruit extracts. J Global
365		Pharma Technol. 2011; 3:14-30.
366	27.	Anagha K, Manasi D, Priya L, Meera M. Scope of Glycyrrhizaglabra (Yashtimadhu) as an
367		Antiviral agent: A Review. Int J CurrMicrobiol App Sci. 2014; 3:657-65.
368	28.	Asl NN, Hosseinzadeh H. Review of antiviral effects of Glycyrrhizaglabra L. and its active
369		component, glycyrrhizin. Journal of Medicinal Plants. 2007; 6:1-12.
370	29.	Sharma U, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active steroidal
371		saponins from Asparagus racemosus. Medicinal Chemistry Research. 2013; 22:573-9. Doi:
372		10.1007/s00044-012-0048-4
373	30.	Karuna DS, Dey P, Das S, Kundu A, Bhakta T. In vitro antioxidant activities of root extract
374		of Asparagus racemosus Linn. Journal of traditional and complementary medicine. 2018;
375		8(1):60-5. Doi: 10.1016/j.jtcme.2017.02.004

- 376 31. Subramani Paranthaman Balasubramani, Padma Venkatasubramanian, Subrahmanya Kumar
- 377 Kukkupuni Bhushan Patwardhan. Plant-based Rasayana drugs from Ayurveda. Chinese
- Journal of Integrative Medicine; 2011; volume 17: pages88–
- 379 94Doi:<u>https://doi.org/10.1007/s11655-011-0659-5</u>
- 380 32. Maggini S, Pierre A, Calder PC. Immune Function and Micronutrient Requirements Change
- 381 over the Life Course. Nutrients. 2018; 10:1531. Doi: 10.3390/nu10101531
- 382

383 Table 1: Baseline characteristics in two groups

Parameters	SoC + Placebo (n=33)	SoC + IP (n=39)	P value
			(between groups)
Age (years)	43.0 (34.0 - 58.0)	47.0 (40.0 - 56.0)	0.336
Gender			
Male	20 (60.6)	17 (43.6)	0.150
Female	13 (39.4)	22 (56.4)	

384 Data presented as median (IQR) or n (%); *SoC = Standard of Care

385

386 **Table 2: Change in viral load in two groups**

Viral load	SoC + Placebo (N=21)	SoC + IP (N=31)	P value7 (between groups)
Baseline	385670	662081	0.758
	(30807 to 131511846)	(56904 to 19485712)	
Day 4	66845	48963	0.845
	(11978 to 836124.5)	(8774 to 1248257)	
P value	0.106	0.002	

388

389

390 Table 3: Clinical Improvement

NRS score	SoC + Placebo (n=31)	SoC + IP (n=35)	P value (between groups)
Baseline	4.26±1.09	4.3±1.13	0.781
Follow-up	3.16±1.03	$1.74{\pm}1.03$	< 0.0001

P value	< 0.0001	< 0.0001	
WHO Ordinal Scale	SoC + Placebo (n=31)	SoC + IP (n = 35)	
Baseline	1.71 (<u>+</u> 0.78)	1.63 (<u>+</u> 0.84)	0.58
Follow-up	1.26 (<u>+</u> 0.63)	1.03 (<u>+</u> 0.77)	0.33
P value	0.03	0.0001	

391

392 Table 4: Changes in inflammatory and immunological parameters

Parameters	SoC + Placebo (n=14)	SoC + IP (n=15)	P value (between groups)
Total leucocyte count			
Baseline	6257.1±4488.6	7240.0±2580.4	0.472
Follow-up	7200.0±1669.6	7606.7±1547.5	0.502
Change from baseline	942.6 (3005.0 to -1119.3)	366.7 (1720.2 to -986.8)	
P value	0.341	0.570	
Absolute B cell count			
Baseline	193.4±102.6	255.9±154.7	0.215
Follow-up	317.9±213.5	437.3±270.5	0.200
Change from baseline	124.5 (205.1 to 43.8)	181.4 (282.4 to 80.5)	
P value	0.005	0.002	
Absolute T cell count			
Baseline	710.5±389.4	836.8±455.6	0.431
Follow-up	1512.7±477.8	1720.9±611.7	0.319
Change from baseline	802.2 (1094.5 to 510.0)	884.1 (1230.7 to 537.5)	
P value	<0.0001	<0.0001	
Absolute CD3, CD4 and T			
helper cells			
Baseline	399.8±239.1	515.5±314.8	0.278
Follow-up	834.8±261.3	1055.7±417.6	0.102
Change from baseline	435.0 (628.1 to 242.1)	540.2 (737.1 to 343.4)	
P value	<0.0001	<0.0001	
Absolute CD3: CD8			
Baseline	270.7±128.6	299.7±183.5	0.629
Follow-up	571.4±195.7	607.3±258.8	0.679
Change from baseline	300.7 (406.1 to 195.4)	307.6 (455.8 to 159.3)	
P value	<0.0001	0.001	
Absolute Treg counts			
Baseline	5.9±5.0	6.5±7.1	0.817
Follow-up	3.6±2.7	4.8±2.9	0.244
Change from baseline	-2.3 (0.35 to -5.1)	-1.7 (2.1 to -5.3)	
P value	0.082	0.358	
Absolute NK Cell count			
Baseline	10.4±9.0	9.9±11.4	0.898
Follow-up	17.6±9.5	28.3±32.5	0.248
Change from baseline	7.2 (13.0 to 1.3)	18.3 (38.1 to -1.5)	


P value	0.020	0.067	
Neutrophils (%)			
Baseline	63.7±16.6	63.9±17.1	0.969
Follow-up	54.4±7.9	51.7±9.3	0.422
Change from baseline (95% CI)	-9.3 (-1.5 to -17.0)	-12.2 (-2.6 to -21.9)	
P value	0.023	0.017	
Absolute neutrophil count			
Baseline	4457.1±4597.1	4615.4±2562.2	0.914
Follow-up	3985.7±1346.1	4046.1±1158.0	0.902
Change from baseline (95% CI)	-3555.4 (1581.4 to -2524.3)	-569.3 (799.3 to -1937.8)	
P value	0.628	0.383	
Lymphocyte (%)			
Baseline	25.7±12.6	27.2±14.7	0.776
Follow-up	32.8±7.1	37.0±7.0	0.135
Change from baseline (95% CI)	7.1 (13.7 to 0.5)	9.8 (18.5 to 1.1)	
P value	0.036	0.031	
Absolute lymphocyte counts			
Baseline	1250.0±462.7	1653.8±773.1	0.109
Follow-up	2342.9±734.5	2846.1±810.0	0.103
Change from baseline (95% CI)	1092.9 (1515.0 to 670.7)	1192.3 (1698.8 to 685.8)	
P value	< 0.0001	< 0.0001	
Th cell response	SoC + Placebo	SoC + IP	
Ab Th1			
Baseline	209.5 (45.3 to 419.8)	164 (27 to 501)	0.861
Follow-up	347 (215.8 to 529.3)	430 (235 to 683)	0.338
P value for change	0.098	0.023	
Ab Th2			
Baseline	143 (66.5 to 230)	164 (80 to 398)	0.318
Follow-up	424 (343.7 to 593.8)	593 (351 to 768)	0.338
P value for change	0.005	0.003	
Antibody levels	SoC + Placebo	SoC + IP	
IgG			
Baseline	1301.4±284.9	1593.6±309.5	0.015
Follow-up	1132.3±223.9	1356.6±260.5	0.021
Change from baseline (95% CI)	-169.1 (-42.9 to -295.4)	-237.0 (-79.9 to -394.1)	
P value	p=0.012	p=0.007	
IgM	•	•	
Baseline	117.7±77.2	98.8±40.6	0.438
Follow-up	113.0±62.9	89.9±28.4	0.420
Change from baseline (95% CI)	-4.7 (8.2 to -17.5)	-8.9 (8.8 to -26.7)	
P value	p=0.450	p=0.295	
COVID Antibodies	Placebo	Drug	
	5.1±2.5	6.0±2.7	0.353

393

394

395 Figure Legends

396 Image 1: Treatment administration in two groups



398

